PubMed Health⌕ Search

Biomedical subjects

C A de Jong

Publications and source records attributed to C A de Jong.

12 recordsLinked to original sources

[Psychiatric research in Southern Netherlands; most studies get completed, social-scientific ones more often than pharmacotherapeutical trials].

OBJECTIVE: To describe the nature and the course of scientific studies in psychiatry that have been reviewed by the Research Ethics Committee in the South Netherlands (Toetsingscommissie Zuid-Nederland (TCZ)). DESIGN: Exploratory, retrospective. METHOD: Scientific studies in psychiatry that were submitted for review in the period 1 January 1988-31 December 1998 by TCZ, were investigated to determine their progress and to find out what study features were prognostic for completion. RESULTS: In this research project 131 psychiatric studies, which were expected to be completed towards the end of 1998, were considered for inclusion. Approximately 2/3 of all studies had a social-scientific character, 1/3 being pharmacotherapeutical. 116 cases were reviewed and 114 selected. From the 88 studies started, 77 had been completed. Out of these 77 completed studies 75 have been presented and/or published. Seven patients were involved in four studies that were stopped prematurely; they were possibly incorrectly burdened. Studies described as experimental, painful, pharmacotherapeutical, externally initiated, externally financed or multicentered ran a greater risk of not being completed than studies without these characteristics. Topics such as a limited number of subjects, a large burden or a long duration also jeopardized the successful completion of a study. A multivariate analysis showed that the pharmacotherapeutical nature of studies was the most important predictor. CONCLUSION: In the psychiatric hospitals of the South Netherlands scientific research has been carried out. Many of the studies that were approved by the TCZ were started and completed. Pharmacotherapeutical research ran a greater risk of non-completion than social-scientific research.

Clinical Trials as Topic↗

Effect of timolol with and without preservative on the basal tear turnover in glaucoma.

AIMS: The purpose of this study was to assess whether the preservative benzalkonium chloride (BAC 0.01%) present in timolol induced a decrease in basal tear turnover and a deterioration of precorneal tear film in patients with glaucoma and ocular hypertension using topical timolol. METHODS: The basal tear turnover of 20 patients with open angle glaucoma or ocular hypertension was measured by computerised objective fluorophotometry when using topical timolol preserved with BAC and 2 weeks after changing to topical timolol containing no preservative. Evaluation of the precorneal tear film was done by measuring the break up time (BUT) before and 2 weeks after changing medication. RESULTS: The tear turnover of the patients before the change was 32% lower than that of healthy controls (mean tear turnover values (SD) (%/min): 10.7 (3.0) and 15.6 (5.4), respectively, p < 0.0001). A mean increase of 28% (47%) in the individual tear turnover values was found after the change to the preservative-free timolol (p = 0.04). The BUT values before the change of medication did not differ significantly from those after the change (p = 0.5) but both values were significantly lower than the values of healthy controls (p = 0.009 and p = 0.003, respectively). CONCLUSION: Preservative-free timolol solution has a favourable effect on the tear turnover of patients with glaucoma and ocular hypertension in comparison with timolol containing BAC. The integrity of the precorneal tear film persisted to be affected when using timolol without BAC. Timolol without preservative can be recommended in those patients who have keratoconjunctivitis sicca or a borderline tear production since BAC may exacerbate a dry eye state.

Benzalkonium Compounds↗

Sequence analysis of cDNA derived from reticulocyte mRNAs coding for Rh polypeptides and demonstration of E/e and C/c polymorphisms.

RNA derived from enriched reticulocytes of Rh-phenotyped donors was isolated, reversely transcribed into cDNA and amplified with Rh-specific primers by polymerase chain reaction. Nucleotide sequence analysis of the entire coding region of the Rh cDNAs was carried out. Four types of cDNAs were identified, tentatively designated as RhSCI, RhSCII, RhSCIII and RhSCIV. Comparison of RhSCII with RhSCI (identical to the previously reported RhIXb/30A cDNA), showed single base pair difference. Since RhSCI and RhSCII were found to be related to the presence of E or e antigen, respectively, the P226A amino acid polymorphism appears to be the genetic basis of the E/e polymorphism. RhSCIII was demonstrated to be a transcript derived from the RhD gene, with 35 amino acid substitutions as compared to RhSCI. RhSCIV was found to be present only in RhC-positive individuals, indicating that RhSCIV encodes a polypeptide carrying the C antigen. Six nucleotide changes, resulting in four amino acid substitutions W16C, L60I, N68S and P103S, were observed between RhSCII and RhSCIV, probably representing the C/c polymorphism.

Amino Acid Sequence↗

No effect of negative mood on the alcohol cue reactivity of in-patient alcoholics.

Forty in-patient alcoholics were exposed to an alcohol cue (holding and smelling an alcoholic drink) while in a negative mood, and while in a neutral mood. For the negative mood condition either a distressing or depressing Mood Induction Procedure (MIP) was used. In the control condition, a neutral MIP was used. In the negative mood condition, the subjects were found to be more distressed, more irritated, less calm, and less satisfied than in the neutral mood condition. In all conditions, following exposure to the alcohol cue, the desire to drink, systolic blood pressure, and heart rate variability increased, while self-efficacy beliefs to resist the urge to drink, and heart rate decreased. In sum, alcohol cue reactivity was observed, but not in response to a negative as opposed to a neutral mood or a distressed versus a depressed mood.

Adult↗